FDA’s Push for New COVID-19 Vaccines Despite Diminished Virus Impact and Safety Concerns

The FDA’s vaccine advisory committee unanimously recommended a monovalent JN.1-lineage vaccine composition for COVID-19 vaccines for 2024-2025. Dr. David Wiseman raised concerns about the potential health risks of continued COVID-19 vaccination, citing a lack of testing for cancer effects and undisclosed SV40 sequences in Pfizer’s vaccine. The committee’s decision drew criticism from some medical professionals, who called for the removal of COVID-19 vaccines from the market. CDC data presented at the meeting showed that COVID-19 hospitalizations, positive tests, and deaths are at all-time lows.

Editor’s Note: These warnings about untested cancer effects and undisclosed SV40 sequences in Pfizer’s vaccine highlight the troubling lack of transparency and safety testing. It is troubling that despite these health risks, the committee still recommends new vaccine compositions.

It seems counterintuitive to promote further vaccination when the virus impact has drastically diminished, with hospitalizations, positive tests, and deaths at historic lows. This situation reflects a disregard for reported side effects and the need for a thorough study of these vaccines’ long-term effects.

Read Original Article